DSM Biomedical materials and technologies support orthopedic applications, including spine, trauma and sports medicine. Learn more.
17 Sep 2018, by Brad Perriello
The National Football League Players Assn. got in on a nearly $23 million Series A round for Miach Orthopaedics and its knee repair technology, the Boston-based company said today.
Miach is developing bio-engineered implants for surgical connective tissue repair, aiming first at anterior cruciate ligament repair with its Bridge-Enhanced ACL Repair product, a sponge that’s designed to act as a scaffold to stimulate healing.
The $22.5 million A round, co-led by Amzak Health Investors and DSM Venturing, also included the NFLPA and other investors, Miach said. The proceeds are earmarked for ongoing clinical work and fast-tracking the manufacturing process for the BEAR implant, the company said, noting that it’s treated nearly 100 patients in a clinical study.
“We believe that BEAR technology has the potential to transform connective tissue repair, and we’re gratified that Amzak, DSM and the NFL Players Assn. share our vision to explore its application in ACL repair,” founder Dr. Martha Murray, of Boston Children’s Hospital, said in prepared remarks. “We look forward to accelerating clinical trials to further evaluate the less-invasive BEAR technology as a viable alternative to ACL reconstruction.”
DSM portfolio of innovative biomedical materials and process manufacturing technologies: Biomedical Polyethylenes, Biomedical polyurethanes, Collagen Technology, Device Development, and Extracellular Matrix (ECM) Technology. Learn more.
DSM Biomedical offers the broadest portfolio of biomedical materials and manufacturing across market applications, including orthopedics, ophthalmology, neurology, cardiology, diabetes, wound, and continence care.
Excelling in medical device partner services, DSM Biomedical supports our customers end-to-end.